Tempero Bio raises $70 million to advance addiction pipeline
US biotech Tempero Bio has raised $70 million in a series B financing and brought in a new chief medical officer as it pushes ahead with clinical development of its lead candidate, TMP-301, for substance use disorders.
The funding round was led by 8VC, with Aditum Bio, Khosla Ventures and others joining in. The capital will support two Phase II studies of TMP-301, targeting alcohol use disorder and cocaine use disorder, as well as Phase III-enabling activities and additional preclinical research.
John Wagner has stepped into the role of chief medical officer, taking over from Bruce Imbert. Dr Wagner previously held the same position at digital biomarker firm Koneksa Health and had a five-year tenure at Takeda (TYO: 4502), where he served as senior vice president of translational research and early clinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze